{"info": {"address1": "614 McKinley Place N.E.", "city": "Minneapolis", "state": "MN", "zip": "55413", "country": "United States", "phone": "612 379 8854", "fax": "612 656 4400", "website": "https://www.bio-techne.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It has strategic partnership with Lunaphore Technologies S.A. to develop automated same-slide spatial multiomics solution. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.", "fullTimeEmployees": 3000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Charles R. Kummeth", "age": 62, "title": "CEO, Pres & Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": 5071187, "exercisedValue": 31638464, "unexercisedValue": 155919776}, {"maxAge": 1, "name": "Mr. James T. Hippel", "age": 51, "title": "Exec. VP of Fin. & CFO", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 1936457, "exercisedValue": 15156880, "unexercisedValue": 19268920}, {"maxAge": 1, "name": "Mr. Kim  Kelderman", "age": 55, "title": "Pres of Diagnostics & Genomics", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 1347547, "exercisedValue": 699551, "unexercisedValue": 6230478}, {"maxAge": 1, "name": "Mr. William A. Geist", "age": 52, "title": "Pres of Protein Sciences Segment", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 904200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "David  Clair", "title": "Sr. Director of Investor Relations & Corp. Devel.", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shane  Bohnen", "title": "Sr. VP, Gen. Counsel & Corp. Sec.", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gerry  Andros", "title": "VP of Sales and Marketing", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert M. Gavin", "age": 54, "title": "VP of Corp. Devel.", "yearBorn": 1968, "fiscalYear": 2018, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Brenda S. Everson", "title": "Sr. VP & Chief HR Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Luca  Cicchetti", "title": "Managing Director", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 1, "overallRisk": 7, "governanceEpochDate": 1680307200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 85.23, "open": 85.45, "dayLow": 83.73, "dayHigh": 85.51, "regularMarketPreviousClose": 85.23, "regularMarketOpen": 85.45, "regularMarketDayLow": 83.73, "regularMarketDayHigh": 85.51, "dividendRate": 0.32, "dividendYield": 0.0038, "exDividendDate": 1675987200, "payoutRatio": 0.1991, "fiveYearAvgDividendYield": 0.5, "beta": 1.252249, "trailingPE": 52.378883, "forwardPE": 35.58228, "volume": 1162254, "regularMarketVolume": 1162254, "averageVolume": 1029447, "averageVolume10days": 1466190, "averageDailyVolume10Day": 1466190, "bid": 0.0, "ask": 0.0, "bidSize": 800, "askSize": 800, "marketCap": 13263001600, "fiftyTwoWeekLow": 68.0025, "fiftyTwoWeekHigh": 107.065, "priceToSalesTrailing12Months": 11.8436575, "fiftyDayAverage": 75.3954, "twoHundredDayAverage": 80.90825, "trailingAnnualDividendRate": 0.32, "trailingAnnualDividendYield": 0.0037545464, "currency": "USD", "enterpriseValue": 13355419648, "profitMargins": 0.2338, "floatShares": 155821977, "sharesOutstanding": 157275008, "sharesShort": 2411926, "sharesShortPriorMonth": 2562938, "sharesShortPreviousMonthDate": 1677542400, "dateShortInterest": 1680220800, "sharesPercentSharesOut": 0.0153, "heldPercentInsiders": 0.0089300005, "heldPercentInstitutions": 0.96579003, "shortRatio": 2.84, "shortPercentOfFloat": 0.0199, "impliedSharesOutstanding": 0, "bookValue": 11.631, "priceToBook": 7.250452, "lastFiscalYearEnd": 1656547200, "nextFiscalYearEnd": 1688083200, "mostRecentQuarter": 1672444800, "earningsQuarterlyGrowth": -0.376, "netIncomeToCommon": 261736992, "trailingEps": 1.61, "forwardEps": 2.37, "pegRatio": 3.94, "lastSplitFactor": "4:1", "lastSplitDate": 1669766400, "enterpriseToRevenue": 11.926, "enterpriseToEbitda": 37.948, "52WeekChange": -0.2055769, "SandP52WeekChange": -0.06829989, "lastDividendValue": 0.08, "lastDividendDate": 1675987200, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TECH", "underlyingSymbol": "TECH", "shortName": "Bio-Techne Corp", "longName": "Bio-Techne Corporation", "firstTradeDateEpochUtc": 603037800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "0b57ad1b-1e0c-399e-a299-48cc57d56404", "messageBoardId": "finmb_189488", "gmtOffSetMilliseconds": -14400000, "currentPrice": 84.33, "targetHighPrice": 120.0, "targetLowPrice": 89.0, "targetMeanPrice": 101.2, "targetMedianPrice": 100.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 13, "totalCash": 196756000, "totalCashPerShare": 1.251, "ebitda": 351940992, "totalDebt": 289158016, "quickRatio": 2.971, "currentRatio": 4.402, "totalRevenue": 1119840000, "debtToEquity": 15.826, "revenuePerShare": 7.137, "returnOnAssets": 0.07711, "returnOnEquity": 0.14834, "grossProfits": 758092000, "freeCashflow": 219363504, "operatingCashflow": 296310016, "earningsGrowth": -0.367, "revenueGrowth": 0.009, "grossMargins": 0.68328005, "ebitdaMargins": 0.31428, "operatingMargins": 0.25715, "financialCurrency": "USD", "trailingPegRatio": null}, "news": [{"uuid": "7b83d4bc-7c4d-3139-9502-cc7cfd08871c", "title": "BIO-TECHNE AND LUNAPHORE ESTABLISH STRATEGIC PARTNERSHIP TO DEVELOP THE FIRST FULLY AUTOMATED SAME-SLIDE SPATIAL MULTIOMICS SOLUTION", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/bio-techne-lunaphore-establish-strategic-110000239.html", "providerPublishTime": 1681729200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ZSrp3Stp1YgJ.r2AVcDu7A--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b1b9241f6a5346a7eaf02583c53df450", "width": 400, "height": 225, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/_zhg52dei9SOYCShplD9bA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/b1b9241f6a5346a7eaf02583c53df450", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["TECH"]}, {"uuid": "8d8d32f9-7fc2-3cc5-be9f-081ebe0dea3c", "title": "BIO-TECHNE TO SHOWCASE INNOVATIVE CANCER RESEARCH, CELL THERAPY AND MANUFACTURING TOOLS AT AACR 2023 CONFERENCE", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/bio-techne-showcase-innovative-cancer-110000320.html", "providerPublishTime": 1681383600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/MwvKmGeHTYh_XWLc9BX5ZA--~B/aD0xMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1958f6812cdfdc125df1b388c1ee080c", "width": 400, "height": 100, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/.zZrW.MlkprGnxrZOGH_rg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/1958f6812cdfdc125df1b388c1ee080c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["TECH"]}, {"uuid": "98aecdf4-eb09-36ff-bccc-95e0922ddd9a", "title": "BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 3, 2023, TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/bio-techne-host-conference-call-110000609.html", "providerPublishTime": 1681297200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/MwvKmGeHTYh_XWLc9BX5ZA--~B/aD0xMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1958f6812cdfdc125df1b388c1ee080c", "width": 400, "height": 100, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/.zZrW.MlkprGnxrZOGH_rg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/1958f6812cdfdc125df1b388c1ee080c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["TECH"]}, {"uuid": "5364c745-f3fd-378b-8db2-bd9a5f7106eb", "title": "At US$75.19, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/us-75-19-bio-techne-102422031.html", "providerPublishTime": 1681208662, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/6yvSv34WjsBU70VeapBSyg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["TECH"]}, {"uuid": "d09b5a70-3d34-327b-8b91-dd2031762b9e", "title": "BIO-TECHNE CELEBRATES MILESTONE WITH MORE THAN 1,000 ELLA\u2122 INSTRUMENTS NOW IN OPERATION", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/bio-techne-celebrates-milestone-more-110000810.html", "providerPublishTime": 1680692400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/MwvKmGeHTYh_XWLc9BX5ZA--~B/aD0xMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1958f6812cdfdc125df1b388c1ee080c", "width": 400, "height": 100, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/.zZrW.MlkprGnxrZOGH_rg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/1958f6812cdfdc125df1b388c1ee080c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["TECH"]}, {"uuid": "38472451-1237-3dee-84c0-239c91aa580c", "title": "BIO-TECHNE COMPLETES INVESTMENT IN WILSON WOLF MANUFACTURING", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/bio-techne-completes-investment-wilson-110000802.html", "providerPublishTime": 1680519600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/MwvKmGeHTYh_XWLc9BX5ZA--~B/aD0xMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1958f6812cdfdc125df1b388c1ee080c", "width": 400, "height": 100, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/.zZrW.MlkprGnxrZOGH_rg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/1958f6812cdfdc125df1b388c1ee080c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["TECH"]}, {"uuid": "737f5b70-b0f3-3c43-8cf3-0ef5c65708f0", "title": "Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/now-time-put-bio-techne-104529860.html", "providerPublishTime": 1679913929, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/6yvSv34WjsBU70VeapBSyg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["TECH"]}, {"uuid": "fde68760-e1ab-359d-982f-87b4e4f5d56b", "title": "BIO-TECHNE ANNOUNCES COMPLETION OF CELL AND GENE THERAPY CATAPULT PROCESS ANALYTICAL TECHNOLOGY (PAT) CONSORTIUM", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/bio-techne-announces-completion-cell-110000995.html", "providerPublishTime": 1678878000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/MwvKmGeHTYh_XWLc9BX5ZA--~B/aD0xMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1958f6812cdfdc125df1b388c1ee080c", "width": 400, "height": 100, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/.zZrW.MlkprGnxrZOGH_rg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/1958f6812cdfdc125df1b388c1ee080c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["TECH"]}]}